| Project Detail |
Gene therapy offers a promising opportunity for treating the more than 10,000 human genetic diseases, as well as other disorders, such as cancer, by editing disease-causing genetic defects or engineering immune cells to target cancer cells. However, most genetic disorders remain untreatable, as gene therapy still holds an untapped potential due to significant limitations of current editing technologies, that are not efficient, precise and safe enough and thus, present limitations in scope and applicability. Integra Therapeutics, a spin-off of the Pompeu Fabra University (UPF) has developed an advanced genome writing platform that overcomes the limitations of current gene editing technologies. Our proprietary gene writing technology platform- FiCAT combines the precision of RNA-guided nucleases with the effectiveness of programmable transposases to insert large pieces of DNA in a safe, precise and stable way. FiCAT has the capacity to integrate virtually any gene into the genome with unprecedented efficiency, precision and safety. FICAT has already been validated in several ex vivo and in vivo models. With FiCAT, we will unlock the potential of gene writing to cure genetic diseases and bring life-changing therapies to patients suffering from high unmet need genetic and neoplastic diseases. |
